Renin Angiotensin SyStem blockade: diabetes nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN65752530

Enrollment

285

Registered

2004-07-22

Start date

1997-03-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy (DN) Nutritional, Metabolic, Endocrine Diabetic Nephropathy (DN)

Interventions

1. Angiotensin-Converting Enzyme (ACE) inhibitor: Enalapril 2. Angiotensin Receptor Blocker: Losarten

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type one diabetes 2. Normal Glomerular Filtration Rate (GFR) and Blood Pressure (BP) 3. Normoalbuminuria 4. Either sex, 18 to 64 years of age

Exclusion criteria

Exclusion criteria: 1. Type one Diabetes Mellitus longer then 20 years 2. BP more than 135/85 mmHg 3. GFR less than 90 ml/min 4. Microalbuminuria 5. Soiltary kidney 6. Other chronic disease 7. Pregnancy or planning pregnancy within two years of randomisation

Design outcomes

Primary

Measure	Time frame
The primary outcome is to determine, in Type one diabetes without clinical evidence of diabetic nephropathy, if inhibition of the renin-angiotensin system activity can prevent or retard the rate of development of the histologic lesions associated with diabetic nephropathy.	—

Secondary

Measure	Time frame
1. Retinopathy 2. Microalbuminuria 3. Blood pressure 4. GFR 5. Creatinine	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026